S. Deudon

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Thomas Bachelot, Florence Dalenc, Fabrice André, 2013, Clinical Cancer Research.

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

P. Neven, A. Musolino, K. Blackwell, 2017, Breast Cancer Research.

Predictive Biomarkers and Personalized Medicine Targeting FGFR with Dovitinib ( TKI 258 ) : Preclinical and Clinical Data in Breast Cancer

H. Rugo, M. Campone, M. Shi, 2013 .

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

G. Scagliotti, Serafino Pantano, C. Gridelli, 2017, The Lancet. Oncology.

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study

G. Scagliotti, C. Gridelli, A. Shaw, 2016 .

Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled

P. Neven, A. Musolino, K. Blackwell, 2013 .

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.

E. Felip, R. Caparica, M. Garassino, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.